Karuna Therapeutics Inc (KRTX)

Karuna Therapeutics Inc Aktie (KRTX) Neueste Nachrichten

New Strong Buy Stocks for May 13th - Yahoo News UK

Yahoo News UK

Zurcher Kantonalbank Zurich Cantonalbank Purchases 550 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) - Defense World

Defense World

Anthos Therapeutics Announces Appointment of Bill Meury as CEO - GlobeNewswire

GlobeNewswire

Karuna Investor Ends Suit After Bristol-Myers Seals $14B Deal - Law360

Law360

Seaport debuts with $100M Series A, as psychiatric boom grows - STAT

STAT

PureTech calls new spinout Seaport Therapeutics 'Karuna on steroids' - Boston Business Journal - The Business Journals

The Business Journals

Bristol Myers Squibb concludes acquisition of Karuna Therapeutics - Medical Dialogues

Medical Dialogues

PureTech made millions on Karuna acquisition. Here's what it plans to return to shareholders. - Boston Business Journal - The Business Journals

The Business Journals

PureTech made millions on Karuna acquisition. Here's what it plans to return to shareholders. - Boston Business Journal - The Business Journals

The Business Journals

Strike While The Market Is Hot

Seeking Alpha

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion - citybiz

citybiz

Karuna Therapeutics Undergoes Extensive Corporate Transformation - TipRanks.com - TipRanks

TipRanks

Bristol Myers Squibb completes Karuna Therapeutics buyout By Investing.com - Investing.com

Investing.com

When Will Karuna Therapeutics, Inc. (NASDAQ:KRTX) Turn A Profit? - Simply Wall St

Simply Wall St

Karuna Therapeutics set to merge with Bristol-Myers Squibb - Investing.com Nigeria

Investing.com Nigeria

Chief Medical Officer Stephen Brannan Sells 5,000 Shares of Karuna Therapeutics Inc (KRTX) - Yahoo Finance

Yahoo Finance

Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short Position - Yahoo Finance

Yahoo Finance

Minerva setback doesn't preclude big year for schizophrenia - BioCentury

BioCentury

Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect

Benzinga

Karuna Therapeutics stock drops on no apparent news amid deal with Bristol-Myers Squibb - Seeking Alpha

Seeking Alpha

Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout

Zacks Investment Research

Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout - Yahoo Finance

Yahoo Finance

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business ... - Business Wire

Business Wire

Karuna Therapeutics: Getting Sold Short (NASDAQ:KRTX) - Seeking Alpha

Seeking Alpha

Asset Class And Stock Performance Since 10/27/23

Seeking Alpha

This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space

Benzinga

Karuna Faces Investor Suit Over $14B Bristol Myers Buyout - Law360

Law360

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst

Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc ... - GlobeNewswire

GlobeNewswire

Bristol Myers Squibb results top expectations as newer drugs help fuel growth

MarketWatch

Karuna Therapeutics (KRTX) Rose on Acquisition Announcement - Yahoo Finance

Yahoo Finance

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc ... - GlobeNewswire

GlobeNewswire

Karuna's KarXT is Evaluate's most anticipated drug for 2024 - Seeking Alpha

Seeking Alpha

Mizuho Downgrades Karuna Therapeutics: Here's What You Need To Know

Benzinga

KARUNA THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick ... - PR Newswire

PR Newswire

Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024 - BioCentury

BioCentury

Another company bid against BMS' $14B offer for Karuna - Fierce Biotech

Fierce Biotech

Bullish Continuation in '24? 3 Market Areas to Watch

Zacks Investment Research

4Q23 Wrap: Turning up - BioCentury

BioCentury

Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion - European Pharmaceutical Manufacturer

European Pharmaceutical Manufacturer

Where Are They Now Karuna Therapeutics - Life Science Leader Magazine

Life Science Leader Magazine

Bristol-Myers Squibb's Winning Formula: Dividends, M&A, And Innovation

Seeking Alpha

Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data

Zacks Investment Research

Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday

Benzinga

Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data - Yahoo Finance

Yahoo Finance

Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B

Zacks Investment Research

Yes Virginia, There Is a Santa Claus Rally

Zacks Investment Research

Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst

Benzinga

Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers

Zacks Investment Research

Company News for Dec 26, 2023

Zacks Investment Research